The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2015.12.002PMID 26708040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

  2015cited by this paper
• Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Rapid eradication of a bulky melanoma mass with one dose of immunotherapy.

  2015cited by this paper
• Managing immune checkpoint-blocking antibody side effects.

  2015cited by this paper
• Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature

  2015cited by this paper
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

  2015cited by this paper
• Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.

  2015cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

  2014cited by this paper
• Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases

  2014cited by this paper
• MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Reversal of natural killer cell exhaustion by TIM-3 blockade

  2014cited by this paper
• Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Universes collide: combining immunotherapy with targeted therapy for cancer.

  2014cited by this paper
• Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

  2014cited by this paper
• Therapeutic vaccines for cancer: an overview of clinical trials

  2014cited by this paper
• Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).

  2014cited by this paper
• Molecular Pathways Molecular Pathways : CDK 4 Inhibitors for Cancer Therapy

  2014cited by this paper
• Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib

  2014cited by this paper
• Prognostic and predictive markers for the new immunotherapies.

  2014cited by this paper
• Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study

  2014cited by this paper
• Ipilimumab in the treatment of metastatic melanoma: management of adverse events

  2014cited by this paper
• Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

  2014cited by this paper
• Chimeric antigen receptor therapy for cancer.

  2014cited by this paper
• MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

  2014cited by this paper
• Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

  2014cited by this paper
• CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).

  2013cited by this paper
• Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.

  2013cited by this paper
• Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)

  2013cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• Vaccines against advanced melanoma.

  2013cited by this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Which drug, and when, for patients with BRAF-mutant melanoma?

  2013cited by this paper
• Neurological immune-related adverse events of ipilimumab

  2013cited by this paper
• Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.

  2013cited by this paper
• Resistance to BRAF-targeted therapy in melanoma.

  2013cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

  2013cited by this paper
• Ipilimumab-induced acute severe colitis treated by infliximab.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

  2013cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

  2012cited by this paper
• RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

  2012cited by this paper
• Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

  2012cited by this paper
• Progression of RAS-mutant leukemia during RAF inhibitor treatment.

  2012cited by this paper
• Ipilimumab-induced immune-related renal failure--a case report.

  2012cited by this paper
• Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

  2012cited by this paper
• Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

  2012cited by this paper
• Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition

  2012cited by this paper
• Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  2012cited by this paper
• Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

  2012cited by this paper
• The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Melanoma brain metastasis: overview of current management and emerging targeted therapies

  2012cited by this paper
• Screening and Prevention Measures for Melanoma: Is There a Survival Advantage?

  2012cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• KIT as a therapeutic target in metastatic melanoma.

  2011cited by this paper
• Vemurafenib for melanoma metastases to the brain.

  2011cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

  2011cited by this paper
• Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

  2011cited by this paper
• Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

  2011cited by this paper
• Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

  2011cited by this paper
• Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

  2010cited by this paper
• Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• Current systemic therapy for metastatic melanoma

  2009cited by this paper
• MEK1 mutations confer resistance to MEK and B-RAF inhibition

  2009cited by this paper
• Anti-CTLA4 antibody-induced lupus nephritis.

  2009cited by this paper

• Synthetic and Biogenic Materials for Oral Delivery of Biologics: From Bench to Bedside.

  2025cites this paper
• Oxygenated collagenase nanoliposomes for deep photodynamic therapy via remodelling the tumor extracellular matrix.

  2025cites this paper
• Implications for medication safety and adherence in dermato‐oncology: The AMBORA care program for oral antitumor therapeutics

  2025cites this paper
• Metformin's Hidden Power: Unveiling Its Role in Melanoma Suppression Through endo-lysosome pH and Autophagy Regulation.

  2025cites this paper
• Auswirkungen auf die Arzneimitteltherapiesicherheit und Adhärenz in der Dermato‐Onkologie: Das AMBORA‐Therapiebegleitungskonzept für orale Antitumortherapeutika

  2025cites this paper
• New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies

  2024cites this paper
• Impact of senescence cell signature in patients with non-small cell carcinoma and melanoma receiving PD-L1/PD-1 inhibitors.

  2024cites this paper
• LPCAT1 promotes melanoma cell proliferation via Akt signaling

  2024cites this paper
• PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil

  2023cites this paper
• Long-term outcomes of margin-controlled excision for eyelid melanoma

  2023cites this paper
• Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy

  2023cites this paper
• A novel mitochondria‐targeting compound exerts therapeutic effects against melanoma by inducing mitochondria‐mediated apoptosis and autophagy in vitro and in vivo

  2023cites this paper
• The future of cancer immunotherapy: DNA vaccines leading the way

  2023cites this paper
• Systematic review and network meta-analysis of drug combinations suggested by machine learning on genes and proteins, with the aim of improving the effectiveness of Ipilimumab in treating Melanoma.

  2023cites this paper
• Real‐world treatment patterns and outcomes for patients with advanced melanoma treated with immunotherapy or targeted therapy

  2023cites this paper
• GPP-TSAIII nanocomposite hydrogel-based photothermal ablation facilitates melanoma therapy

  2023cites this paper
• Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy

  2023cites this paper
• Analysis and prediction of 5-year survival in patients with cutaneous melanoma: a model-based period analysis

  2023cites this paper
• Antiproliferative Imidazo-Pyrazole-Based Hydrogel: A Promising Approach for the Development of New Treatments for PLX-Resistant Melanoma

  2023cites this paper
• Differences in the phospholipid profile of melanocytes and melanoma cells irradiated with UVA and treated with cannabigerol and cannabidiol

  2023cites this paper
• C118P exerted potent anti-tumor effects against melanoma with induction of G2/M arrest via inhibiting the expression of BUB1B.

  2022cites this paper
• Independent Drug Action in Combination Therapy: Implications for Precision Oncology

  2022cites this paper
• Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma.

  2022cites this paper
• Anandamide-Modulated Changes in Metabolism, Glycosylation Profile and Migration of Metastatic Melanoma Cells

  2022cites this paper
• Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells

  2022cites this paper
• Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review

  2022cites this paper
• Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis

  2021cites this paper
• Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer

  2021cites this paper
• Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.

  2021cites this paper
• RTP4 is a novel prognosis-related hub gene in cutaneous melanoma

  2021cites this paper
• Glucose-Lipopeptide Conjugates Reveal the Role of Glucose Modification Position in Complexation and the Potential of Malignant Melanoma Therapy.

  2021cites this paper
• Identification of Potential Prognostic Biomarkers Associated With Cancerometastasis in Skin Cutaneous Melanoma

  2021cites this paper
• A Novel Small-Molecule Inhibitor Displays Its Therapeutic Potency Through Mitochondria-Mediated Apoptosis And Autophagy In Melanoma

  2021cites this paper
• Protein expression of prognostic genes in primary melanoma and benign nevi

  2021cites this paper
• A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment

  2021cites this paper
• PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice

  2020cites this paper
• Endothelial MAP2K1 mutations in arteriovenous malformation activate the RAS/MAPK pathway.

  2020cites this paper
• Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

  2020cites this paper
• New Insights into the Role of Sphingolipid Metabolism in Melanoma

  2020cites this paper
• Circ_0079593 facilitates proliferation, metastasis, glucose metabolism and inhibits apoptosis in melanoma by regulating the miR-516b/GRM3 axis

  2020cites this paper
• Melanoma brain metastases: review of histopathological features and immune-molecular aspects

  2020cites this paper
• RNAi-mediated IARS2 knockdown inhibits proliferation and promotes apoptosis in human melanoma A375 cells

  2020cites this paper
• Inhibition of the STAT3 Signaling Pathway Contributes to the Anti-Melanoma Activities of Shikonin

  2020cites this paper
• The promising expedition of the delivery systems for monoclonal antibodies

  2020cites this paper
• Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.

  2019cites this paper
• Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000

  2019cites this paper
• Evaluation of radiation-induced genotoxicity on hu-man melanoma cells (SK-MEL-37) by flow cytometry

  2019cites this paper
• Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin

  2019cites this paper
• CMAR_A_194176 3681..3690

  2019cites this paper
• Common Nevus and Skin Cutaneous Melanoma: Prognostic Genes Identified by Gene Co-Expression Network Analysis

  2019cites this paper
• Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

  2019cites this paper
• Moxifloxacin as an inducer of apoptosis in melanoma cells: A study at the cellular and molecular level.

  2019cites this paper
• Revolutionizing treatment of advanced melanoma with immunotherapy.

  2019cites this paper
• Rescue surgery in a patient with metastatic melanoma and BRAF V600E mutation.

  2018cites this paper
• Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice

  2018cites this paper
• Sex disparity in cancer: roles of microRNAs and related functional players

  2018cites this paper
• Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials

  2018cites this paper
• Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

  2018cites this paper
• Impact of genomics on the surgical management of melanoma

  2018cites this paper
• Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada

  2018cites this paper
• Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

  2018cites this paper
• Apatinib mesylate tablet in the treatment of advanced malignant melanoma

  2018cites this paper
• Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies

  2018cites this paper
• Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma

  2018cites this paper
• Personalisiertes Risikomanagement für das maligne Melanom

  2018cites this paper
• Management of Melanoma Locoregional Recurrence

  2018cites this paper
• Rescue Surgery in a Patient With Metastatic Melanoma and BRAF V600E Mutation

  2018cites this paper
• Predictive Biomarkers and Targeted Therapies in the Skin

  2018cites this paper
• A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging

  2018cites this paper
• apatinib mesylate tablet in the treatment of advanced malignant melanoma

  2018cites this paper
• MicroRNAs role as potential biomarkers and key regulators in melanoma

  2017cites this paper
• Targeted drug delivery to melanoma.

  2017cites this paper
• Molecular genetic and immunotherapeutic targets in metastatic melanoma

  2017cites this paper
• Immunological effects of oncolytic virotherapy in the context of a preclinical model of melanoma

  2017cites this paper
• Management of Adverse Effects by Molecular Targeted Therapy and Immunotherapy

  2017cites this paper
• Modern treatment of Head and Neck Melanoma: Case report and Review of literature

  2017cites this paper
• Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation

  2017cites this paper
• Immunotherapy in advanced melanoma: a network meta-analysis.

  2017cites this paper
• Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells.

  2017cites this paper
• Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition

  2017cites this paper
• Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab

  2017cites this paper
• Juglone potentiates TRAIL‑induced apoptosis in human melanoma cells via activating the ROS‑p38‑p53 pathway.

  2017cites this paper
• Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis

  2017cites this paper
• Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.

  2017cites this paper
• Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.

  2017cites this paper
• Genetic alterations in rare subtypes of melanocytic tumors; towards improved diagnosis and therapy

  2017cites this paper
• Characterization of photoactivatable Prodrugs of Kinase Inhibitors

  2017cites this paper
• Personalisiertes Risikomanagement für das maligne Melanom

  2017cites this paper
• Biopanel identifies expression status of targetable proteins in sinonasal melanoma.

  2016cites this paper
• Ribosomal S6 kinase (RSK) modulators: a patent review

  2016cites this paper
• Contemporary and potential future molecular diagnosis of melanoma

  2016cites this paper
• Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy1

  2016cites this paper
• Anticancer effects of morin-7-sulphate sodium, a flavonoid derivative, in mouse melanoma cells.

  2016cites this paper
• From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.

  2016cites this paper
• Title : From monoclonal antibodies to small molecules : the development of inhibitors targeting the PD-1 / PD-L 1 pathway

  2016cites this paper
• Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions.

  2016cites this paper
• Photoinduced Conversion of Antimelanoma Agent Dabrafenib to a Novel Fluorescent BRAFV600E Inhibitor

  2016cites this paper
• Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.

  2016cites this paper
• Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.

  2016cites this paper
• FACULTAD DE FARMACIA UNIVERSIDAD COMPLUTENSE

  2015cites this paper